Don’t expect population-specific quotas in the US Food and Drug Administration’s long-awaited guidance on diversity action plans for Phase III and pivotal trials.
US FDA Commissioner Robert Califf Says No Formulas For Trial Diversity
The FDA does not appear likely to provide a calculation for sponsors to show clinical trial diversity, but agency officials seem split on how tough to enforce the new regulations intended to ensure all groups are adequately represented.
